Skip to content
PubMed This is a summary of 8 peer-reviewed journal articles Updated
Clinical Immunology · CARD9 Deficiency

Advanced Therapies: Cytokines and Stem Cell Transplant

At a Glance

When CARD9 deficiency causes severe fungal infections that persist or return despite antifungal treatment, specialists may consider immune-boosting cytokines or a stem cell transplant. Cytokines are not standard, and transplant is an uncertain, high-risk last resort.

For most people with CARD9 deficiency, standard antifungal medications and surgical care are enough to manage the condition. However, in cases where infections are particularly stubborn, life-threatening, or keep returning despite high-dose treatment, doctors may look toward advanced therapies [1]. These options aim to boost the immune system rather than just attacking the fungus directly.

Cytokine Therapy (G-CSF and GM-CSF)

Cytokines are natural chemical messengers your immune system uses to communicate.

  • G-CSF (Granulocyte Colony-Stimulating Factor) and GM-CSF (Granulocyte-Macrophage Colony-Stimulating Factor) are the most common cytokines used in this setting [2][3].
  • The Goal: These agents do not restore or replace CARD9 signaling; instead, they are used to help boost myeloid-cell numbers or activity, helping recruit white blood cells to the site of an infection to recognize and kill the fungus [4][2].
  • When It’s Used: This is usually an “add-on” (adjunctive) therapy used alongside standard antifungals, especially for CNS candidiasis (fungal infection of the brain) that isn’t clearing or keeps relapsing [1][3].
  • Outcomes: Small studies and individual case reports have shown that adding these cytokines can lead to clinical remission in patients who were not getting better on antifungals alone [2][4]. However, these are not considered “standard” because evidence for their use in CARD9 deficiency is limited to selected reports. Their use is exceptional and specialist-directed, carrying relevant adverse effects and uncertainty about which cytokine, if any, is appropriate [1].

Hematopoietic Stem Cell Transplant (HSCT)

A stem cell transplant (often called a bone marrow transplant) is a procedure where your own immune system is replaced with a healthy donor’s immune system [5].

  • An Uncertain Option: In other immune disorders, HSCT is a well-known cure. In CARD9 deficiency, it is still considered a “last resort” or secondary option for very specific patients [1][6]. It is not established therapy for most CARD9-deficient patients.
  • Who is it for?: It is usually reserved for people with severe, chronic disease—such as deep, invasive skin and bone infections (dermatophytosis)—that has failed multiple rounds of all other treatments [5][7]. It should only be considered at an expert transplant center experienced with inborn errors of immunity.
  • How it Works: The patient’s “faulty” blood-making cells are cleared out using chemotherapy, and new donor cells (which have a working CARD9 gene) are infused. These new cells can then correctly signal the body to fight fungi [5].

Outcomes and Risks of HSCT

While HSCT offers the hope of a cure, it is a high-risk procedure that must be weighed carefully against the risks of the fungal infection itself.

  • Potential for Remission: In one landmark report, two adults with severe CARD9 deficiency who received transplants achieved “complete clinical remission” [5]. Remarkably, they were eventually able to stop taking antifungal medications entirely after more than three years of successful follow-up [5]. However, having a donor with functional CARD9 does not guarantee a cure or automatically permit antifungal discontinuation.
  • Serious Risks: HSCT can lead to severe complications, including treatment-related mortality, Graft-versus-Host Disease (GvHD) (where the donor cells attack the patient’s body), life-threatening infections while the new immune system is growing, infertility, and organ damage [5][8]. In one case, a patient required a second transplant because their blood counts didn’t recover correctly [5]. If a related donor is used, they must also undergo appropriate genetic evaluation.
  • Current Consensus: Because there are so few reported cases of HSCT for CARD9 deficiency, the medical community still considers its overall value “uncertain” [1]. It is a decision that requires a deep partnership between you, your immunologist, and a specialized transplant team, preferably in a carefully reviewed or research setting [6].

Common questions in this guide

When might G-CSF or GM-CSF be considered for CARD9 deficiency?
These cytokines may be considered as add-on treatment when a fungal infection is severe, persistent, or keeps returning despite antifungal medicine. They are especially discussed for central nervous system candidiasis that is not clearing or is relapsing. They do not correct the underlying CARD9 signaling problem, so their use is exceptional and specialist-directed.
Do cytokines replace antifungal treatment?
No. G-CSF and GM-CSF are generally used alongside standard antifungal medication to support the number or activity of immune cells. Evidence in CARD9 deficiency is limited, so specialists must weigh possible benefits against adverse effects and uncertainty.
When is a stem cell transplant considered for CARD9 deficiency?
A hematopoietic stem cell transplant may be considered only for selected patients with severe, chronic fungal disease that has failed multiple treatments, such as deep invasive skin and bone infections. It is not established treatment for most people with CARD9 deficiency and should be evaluated at an expert transplant center.
Can a stem cell transplant cure CARD9 deficiency and allow antifungal medicines to stop?
Some reported adults with severe CARD9 deficiency achieved complete clinical remission and later stopped antifungal medicines after more than three years of follow-up. However, these cases do not guarantee that transplant will cure every patient, and a donor with working CARD9 does not automatically make stopping antifungals safe.
What are the serious risks of HSCT for CARD9 deficiency?
HSCT can cause treatment-related death, graft-versus-host disease, life-threatening infections while the new immune system develops, infertility, and organ damage. Because the procedure is high risk and experience in CARD9 deficiency is limited, the decision should be made jointly with an immunologist and specialized transplant team.

Get notified when new evidence is published on Predisposition to invasive fungal disease due to CARD9 deficiency.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

References

References (8)
  1. 1

    Inherited CARD9 Deficiency: Invasive Disease Caused by Ascomycete Fungi in Previously Healthy Children and Adults.

    Corvilain E, Casanova JL, Puel A

    Journal of clinical immunology 2018; (38(6)):656-693 doi:10.1007/s10875-018-0539-2.

    PMID: 30136218
  2. 2

    Successful Granulocyte Colony-stimulating Factor Treatment of Relapsing Candida albicans Meningoencephalitis Caused by CARD9 Deficiency.

    Celmeli F, Oztoprak N, Turkkahraman D, et al.

    The Pediatric infectious disease journal 2016; (35(4)):428-31 doi:10.1097/INF.0000000000001028.

    PMID: 26658378
  3. 3

    Impaired RASGRF1/ERK-mediated GM-CSF response characterizes CARD9 deficiency in French-Canadians.

    Gavino C, Hamel N, Zeng JB, et al.

    The Journal of allergy and clinical immunology 2016; (137(4)):1178-1188.e7 doi:10.1016/j.jaci.2015.09.016.

    PMID: 26521038
  4. 4

    Complete clinical remission of invasive Candida infection with CARD9 deficiency after G-CSF treatment.

    Du B, Shen N, Hu J, et al.

    Comparative immunology, microbiology and infectious diseases 2020; (70()):101417 doi:10.1016/j.cimid.2020.101417.

    PMID: 32113042
  5. 5

    Successful Allogenic Stem Cell Transplantation in Patients with Inherited CARD9 Deficiency.

    Queiroz-Telles F, Mercier T, Maertens J, et al.

    Journal of clinical immunology 2019; (39(5)):462-469 doi:10.1007/s10875-019-00662-z.

    PMID: 31222666
  6. 6

    Inborn errors of immunity and invasive fungal infections: presentation and management.

    Paccoud O, Warris A, Puel A, Lanternier F

    Current opinion in infectious diseases 2024; (37(6)):464-473 doi:10.1097/QCO.0000000000001062.

    PMID: 39259685
  7. 7

    Unraveling CARD9 Mutations in Deep Dermatophytosis: A Genetic Gateway to Fungal Invasion and Immune Dysfunction.

    Shaw D, Mudey G, Dogra S, Mehta H

    Journal of fungi (Basel, Switzerland) 2026; (12(6)) doi:10.3390/jof12060451.

    PMID: 42346581
  8. 8

    Management of Invasive Fungal Infections in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation: The Turin Experience.

    Busca A, Cinatti N, Gill J, et al.

    Frontiers in cellular and infection microbiology 2021; (11()):805514 doi:10.3389/fcimb.2021.805514.

    PMID: 35071052

This page is for informational purposes only and does not constitute medical advice. Cytokine therapy and HSCT for CARD9 deficiency require individualized decisions with an immunologist and an expert transplant team.